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Based on these observations, we replaced the plaque formation assay with the β -gal activity assay to obtain viral titers in our routine laboratory practice. We have successfully shortened the periods of time from transfection to preparation of the recombinant proteins in large-scale insect cell suspension cultures. When the baculovirus was concentrated by liquid chromatography as described by Barsoum (1) , the titer determined by plaque assay did not show the correlation with the titer estimated by the β -gal activity assay (data not shown) because our method is not associated with the viral particle itself. Therefore, our method is not applicable for determining viral stock titer after concentration. When the virus preparations were stored at 4°C, both the plaque formation assay and the β -gal activity showed no significant decrease for at least six months (data not shown).
For an accurate estimation, we strongly recommend including a standard virus preparation of known titer in the β -gal activity assay to construct a standard curve for each assay. The ability to distinguish B-cell lymphomas and leukemias from reactive, nonmalignant conditions is essential for clinical management. This distinction may be difficult using conventional immunological and histological techniques, but at the molecular level, neoplastic proliferations are quite different from reactive expansions. B -cell leukemias and lymphomas represent progressive expansion of a clone of neoplastic lymphocytes, and all cells in the clone contain the same unique immunoglobulin (Ig) gene rearrangement. In contrast, reactive conditions are associated with the expansion of many genetically different B cells in response to an antigen, resulting in a polyclonal population containing many different Ig gene rearrangements.
The use of PCR analysis of immunoglobulin genes to distinguish neoplastic from reactive B -cell proliferations is well established (1, 2) . Polyacrylamide gel electrophoresis (PAGE) has conventionally been used to analyze these PCR products, and clonal FR3A products (75-100 bp) are readily identified. However, analysis of the larger FR2A products (200-300 bp) by PAGE may be difficult because polyclonal populations are not always uniform in intensity, and several products of a similar size may appear as a single bright band suggestive of a clonal population.
Analysis of B -cell clonality products using a DNA sequencer greatly An alternative to the use of fluorescent end-labeled primers is the incorporation of fluorescently labeled nucleotides in the PCR mixture to internally label the products. Existing unlabeled primers are used, and no additional modification to the PCR reagent concentrations or thermocycling parameters is required. The cost of purchasing many fluorescently labeled primers is significantly greater than the cost of fluorescently labeled nucleotides. So, to convert several reactions from PAGE to automated fluorescent analysis is cheaper using fluorescently labeled nucleotides than buying newly labeled primers.
For the first time, we report the detection of clonal B-cell populations using fluorescently labeled nucleotides. Two semi-nested reactions were performed using primers described by Brisco et al. (1) (FR2A or FR3A) , 100 ng reverse primer (LJH or VLJH) and 0.6 U AmpliTaq Gold. Two microliters of template DNA (at a concentration of 20 ng/ µ L) were added to the first-round reaction. Then, 1 µ L first-round product and 0.04 µ M R110-labeled dCTP (PE Biosystems) were added to the second-round reactions. Amplification was performed using the model 9600 thermocycler (PE Biosystems). Firstand second-round cycling consisted of 95°C for 10 min, 30 cycles of 94°C for 1 min, 60°C for 1 min and 72°C for 10 min. Two microliters of PCR product were added to 2 µ L loading buffer (5:1:2 formamide, dextran blue and the internal size standard TAMRA 500) and denatured by heating at 94°C for 2 min. Products were separated by electrophoresis on a 4% acrylamide gel using a model 377 ABI DNA Sequencer (PE Biosystems). Analysis was performed using GeneScan ® and Genotyper ™(PE Biosystems) software.
With this technique, we can clearly distinguish between polyclonal and clonal B-cell populations (Figure 1, a  and b) . Once a clonal B-cell population has been identified, it can be used as molecular marker for minimal residual disease monitoring. This method facilitates the detection of a clonal population of known size within a polyclonal population (Figure 1c) , which is difficult using conventional PAGE analysis.
Fluorescently labeled nucleotides may be incorporated into any PCR. In contrast, fluorescently labeled primers are specific for a single PCR. The availability of different fluorescent dye-labeled nucleotides (R110, RG6 and TAMRA) allows a number of different PCR products (e.g., FR2A and FR3A) to be pooled for analysis on the ABI DNA Sequencer. Fluorescent nucleotides can significantly lower the cost of converting many different reactions to fluorescent PCR. We used fluorescently labeled nucleotides in an additional nine reactions, including four multiplex reactions for the detection of clonal T-cell populations (4). In each case, labeled nucleotides at a concentration of 0.04 µ M were simply added to the original reaction mixture. No changes to the PCR mixture or cycling conditions were required. We conclude that the use of fluorescently labeled nucleotides provides a more flexible and economical alternative to end-labeled fluorescent primers for the detection of B-cell clonality and other lymphoproliferative disorders.
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Vol. 29, No. 2 (2000) Figure 1 . Electrophoretic profiles of PCR products. (a) A polyclonal population of cells containing 10 peaks generated using DNA extracted from a reactive lymph node; (b) a single 286-bp clonal peak amplified from a blood sample from a patient with chronic lymphocytic leukemia; (c) a clonal peak of known size (251 bp) surrounded by a polyclonal population. This profile was generated using DNA extracted from a lymph node of a patient with B-cell non-Hodgkin's lymphoma.
Sensitive ELISA for Mouse Erythropoietin
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Erythropoietin (Epo), a cytokine produced in fetal liver and adult kidney, stimulates red blood cell production in mammals (2) . Treatment with recombinant Epo is beneficial for several forms of anemia, and much effort is currently being devoted to establishing gene therapy protocols to deliver the Epo gene (3, 7) . To this end, experimentation in rodents is crucial, and a sensitive assay to detect circulating mouse Epo (mEpo) would be useful.
There is strong biological cross-reactivity between mEpo and human Epo (hEpo) connected with the 80% primary sequence homology between mEpo and hEpo proteins (8). Despite this high degree of homology, immunological assays that are commonly used to detect hEpo are not sensitive enough to accurately measure basal mEpo levels in mouse plasma and serum (1, 5) . Recently, an enzyme-linked immunosorbent assay (ELISA), specific for mEpo, was developed by combining specially prepared anti-mEpo with anti-hEpo purified IgGs (4). However, no mEpo ELISA is yet commercially available.
Here, we describe a simple, fast and highly sensitive ELISA for mEpo that makes use of a combination of readymade and commercially available reagents and solutions. These were provided by R&D Systems (Minneapolis, MN, USA) and Roche Molecular Biochemicals (Mannheim, Germany) and were originally developed for detecting hEpo. The hEpo ELISA kits from these two companies display excellent sensitivity for human Epo but cannot detect mEpo concentrations lower than 20-30 mU/mL (Figure 1 ). Both assays are based on a combination of polyclonal and monoclonal anti-hEpo antibodies. We have tested whether it would be possible to establish a sensitive mEpo ELISA by using a combination of the two different monoclonal antibodies provided by the two kits.
In our ELISA, mEpo is captured on the microtiter plate wells provided in the hEpO ELISA kit from R&D Systems. These plates are precoated with a murine monoclonal antibody (MAb) against hEpo. For detection, the horseradish peroxidase conjugated mouse MAb anti-hEpo (HRP-anti-hEpo, clone HE 1/5.5.11) provided in the hEpo ELISA kit from Roche Molecular Biochemicals is used. The samples (recombinant mEpo for standard curve or mouse plasma/serum) are diluted with the R&D specimen diluent. Fifty microliters diluted samples are added to the R&D microtiter plate wells and incubated at room temperature for 1 h with continuous shaking. The content is then decanted from each well and 50 µ L of the diluted HRP-anti-hEpo MAb from Roche Molecular Biochemicals (dilution: 1:59 with that company's incubation buffer) are added to each well. The plates are incubated for 1 h at room temperature under continuous agitation; the wells are then washed four times with 200 µ L R&D washing buffer. Next, 50 µ L R&D substrate solution are added to each well. After 25 min incubation at room temperature, 25 µ L R&D stop solution are added to each well, and the absorbance values are read with a spectrophotometer at 450 nm (reference wavelength 630 nm) within 15 min. Figure 1 shows a comparison of the standard curves obtained with recombinant mEpo by using either our assay or the hEpo ELISA kits recommended by the two manufacturers. It is evident that combining the monoclonal anti-mEpo antibodies detects mEpo concentrations that are otherwise undetectable by using the two kits separately (Figure 1) . The minimum concentration of mEpo that could be quantified with accuracy using our protocol was 1 mU/mL because the mean plus three standard deviations ( SD ) of the 0 mU/mL standard (background value) was lower than the mean -3 SDof the 1-mU/mL sample.
We used this mEpo ELISA to measure mEpo plasma levels in many Balb/c mice that were six to eight weeks old. Ten microliters of plasma were used for these measurements. In the majority of mice (229 out of 238, 96.2%), plasma mEpo concentration ranged from 1-30 mU/mL with a mean of 8.5 ±4.9 SDmU/mL. Nine mice (3.8%) had mEpo values ranging from 31-98 mU/mL with a mean of 46.7 ± 23.1. Analogous results were obtained in C57/B6 mice. The plasma Epo levels in 27 of 29 mice ranged from 2-20 mU/mL with a mean of 7.8 ± 5.1 SD ; in two mice, they ranged from 39.8-84.5 mU/mL with a mean of 57 ± 24.1 SD .
The precision of the assay was calculated by using the intra-assay coefficient of variations ( CV ) calculated on the mean Epo values of different samples of the same plasma. These were measured 10 times in the same experi -
